ABOUT THE SERVICE
Highly selective and potent small molecule inhibitors targeting TAK1, designed to treat autoimmune and inflammatory diseases. Orally bioavailable and demonstrating in vivo efficacy and pilot safety.
Information is owner-confirmed
Last updated 2 months ago
Price range